Disappointing study results for XOMA
July 22, 2015 at 13:07 PM EDT
XOMA
Corp. (Nasdaq: XOMA) reported disappointing results from a Phase 3
EYE-GUARD-B study of the Behcet's disease uveitis treatment gevokizumab sending the stock price plummeting $3.24 to $1.15.
